Drug intelligence / Profile preview

123I-AV151

Development stage: Phase 1
Lead developer: Institute for Neurodegenerative Disorders
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

123I-AV151 is a radiopharmaceutical imaging agent that incorporates Iodine-123. It is designed to detect beta-amyloid deposition in the brain, serving as a diagnostic tool for conditions such as Alzheimer's disease. The agent is administered via bolus injection and its distribution is visualized using Single-Photon Emission Computed Tomography (SPECT) to identify and quantify amyloid plaques.

Other names: [123I]MNI-330123-I MNI-330

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on 123I-AV151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 123I-AV151.

Explore the full profile